Weight‑management market growth

The surprise is that this market is no longer mostly about gym memberships and meal plans. One April 2026 industry forecast says weight management is becoming a nearly half-trillion-dollar business because prescription drugs, surgery, devices, and remote coaching are now being sold together instead of separately. (prnewswire.com) That forecast puts the global market at about $363.8 billion in 2026 and about $488.4 billion by 2032. The jump implies annual growth of roughly 12.8%, which is fast for a healthcare category this large. (prnewswire.com) The demand side is not hard to see. The World Health Organization says 890 million adults worldwide were living with obesity in 2022, and 2.5 billion adults were overweight. (who.int) In the United States, the Centers for Disease Control and Prevention said in September 2024 that 23 states had adult obesity rates above 35%, and every state was above 20%. That means drugmakers are selling into a problem that is already nationwide, not niche. (cdc.gov) The companies pulling the market upward are not selling the same thing. Novo Nordisk and Eli Lilly sell weekly obesity drugs, while Medtronic sells surgical tools and training for bariatric surgery programs that now increasingly work alongside drug treatment instead of against it. (annualreport.novonordisk.com) (medtronic.com) Novo Nordisk’s 2025 annual report shows how big the drug side has become. Its obesity-care sales reached 82.347 billion Danish kroner in 2025, up 26% in reported terms, and the company said the global branded glucagon-like peptide-1 obesity market grew 104% by volume. (annualreport.novonordisk.com) These medicines are expanding beyond weight loss alone. In March 2024, the United States Food and Drug Administration approved Wegovy to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and overweight or obesity. (fda.gov) Eli Lilly’s Zepbound also moved into a second use. In December 2024, the Food and Drug Administration approved it for moderate to severe obstructive sleep apnea in adults with obesity, making it the first drug cleared for that condition. (fda.gov) That is why “weight management” is turning into a bundle, not a product. A patient can now start with a telehealth visit, move to a weekly injection or daily pill, add diet coaching, and in tougher cases be referred into a surgery program using Medtronic equipment and follow-up education. (medtronic.com) (prnewswire.com) The money will not all land in one place. Drugmakers are grabbing the fastest growth, device makers are adapting surgery to fit around medicines, and insurers and clinics are deciding which combinations they will actually pay for and scale. (annualreport.novonordisk.com) (medtronic.com) (prnewswire.com) So the headline number is really a sign that obesity care is being rebuilt into a long-term treatment business. When a market reaches toward $488.4 billion by 2032, it usually means the winning companies are no longer selling a single fix but a whole care pathway. (prnewswire.com)